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Dendritic cells (DCs) are the most potent antigen-presenting cells. They play a vital role in the initiation of immune response
by presenting antigens to T cells and followed by induction of T-cell response. Reported research in animal studies indicated
that vaccine immunity could be a promising alternative therapy for cancer patients. However, broad clinical utility has not been
achieved yet, owing to the low transfection eﬃciency of DCs. Therefore, it is essential to improve the transfection eﬃciency of
DC-based vaccination in immunotherapy. In several studies, DCs were genetically engineered by tumor-associated antigens or
by immune molecules such as costimulatory molecules, cytokines, and chemokines. Encouraging results have been achieved in
cancer treatment using various animal models. This paper describes the recent progress in gene delivery systems including viral
vectorsandnonviralcarriersforDC-basedgeneticallyengineeredvaccines.Thereverseandthree-dimensionaltransfectionsystems
developed in DCs are also discussed.
1.Introduction
Cancer is a leading cause of death worldwide. Although
progress has been made in cancer therapy with conventional
treatment modalities, such as surgery, chemotherapy, and
radiotherapy over the last several decades [1], the total
numberofcancer-relateddeathsisstillincreasing.Therefore,
there is an urgent requirement to develop novel therapies for
the treatment of cancer. With the rapid developments in the
ﬁelds of immunology and cancer biology, immunotherapy
is expected to play a key role in next-generation cancer
treatment. The goal of immunotherapy is to promote the
patient’s own immune system to kill cancer cells instead of
usingexternalhelpers,thatis,surgeryormedicine.Toinduce
a speciﬁc immune response against cancers, researchers
have designed a variety of antitumor vaccines based on the
molecular identities of tumor-associated antigens (TAAs).
Recent ﬁndings from this line of research suggest that
immunotherapy strategies are feasible and promising [2–4].
DCs are professional and the most potent antigen-
presenting cells (APCs) of T-cell special responses, which
play an important role in initiating and regulating adaptive
immune responses [5]. The major function of DCs in
immune system is capturing exogenous and endogenous
antigens when infection or cancer occurs, and then pre-
senting the antigens to T cells via major histocompatibility
complex (MHC) molecules [6]. Moreover, DCs are also
involvedinregulatingimmunetoleranceandclonalselection
[7, 8]. In 1990, it was ﬁrstly reported that injection of
DCs with protein antigens ex vivo could prime antigen-
speciﬁc response in animal model [9]. After that, several
studies demonstrated that DCs pulsed with TAAs could
produce signiﬁcant therapeutic immunity to tumors with
low toxicity. Because DCs could manipulate the immune2 Clinical and Developmental Immunology
system by enhancing speciﬁc responses to infectious diseases
and cancer, DCs networking system became an attractive
approach in cancer therapy [10, 11].
The results of early studies in animal models and some
preclinical trials indicated that TAA-presenting DC might
be a promising treatment for cancer. However, it is diﬃcult
to induce long-term tumor-speciﬁc immune response in
humans. This may be due to the fact that most TAAs are self-
antigens, which make cancer cells bypass normal immune
protective mechanisms. Therefore, in order to overcome
tolerance against self-antigens, it is necessary for an eﬃcient
vaccine to induce autoimmune responses [12]. Additionally,
the suppressive mechanisms in tumor microenvironment
can also inhibit immune response to malignant cells [13].
Hence, designing and developing an eﬃcient and long-term
DC vaccine, which could speciﬁcally target cancer cells,
is urgently needed. Subsequent studies have shown that
vaccination using DCs in vitro transferred with transgene
encoding TAAs or immunomodulatory proteins are more
eﬃcient than using cells directly pulsed with protein anti-
gens, tumor peptides, lysates, or RNA [14].
This paper focuses on the recent ﬁndings in DC vaccina-
tionsgeneticallyengineeredbyrecombinationbiotechnology
via diﬀerent vectors and overviews the development of gene
delivery systems for DCs.
2.Biological Characteristicsof
DCs andthe Process of DC-Mediated
ImmuneResponse
T h eD C sa r eg e n e r a t e df r o mC D 3 4 + bone marrow stem
cells and from DC precursors in the peripheral blood.
The concentration of DCs in normal tissue and blood is
very low, which makes it diﬃcult to isolate DCs directly
from peripheral blood and bone marrow. Currently, the
prevalent procedure is to diﬀerentiate the monocytes from
peripheral blood and bone marrow to DCs with the help of
leukapheresis technology and stimulation by cytokines [15].
According to biological properties of DCs, they could
be divided into three major groups: plasmacytoid DCs
(pDCs), inﬂammatory DCs (iDCs), and conventional DCs
(cDCs) [16, 17]. cDCs are also named myeloid DC (mDCs)
owing to their typical form and function [18]. They can be
further divided into lymphoid-tissue-resident DCs (splenic,
thymic DCs, etc.) and migratory DCs (Langerhans cells,
dermal DCs, etc.) [19]. Unlike migratory DCs, which
migrate through the lymph, lymphoid-tissue-resident DCs
are located mostly at lymphoid tissues to collect and present
antigens [20]. Both of the mDCs can be further classiﬁed
based on the levels of phenotype protein expression and
function. For example, CD8+ and CD4+ mDCs, which were
found to preferentially express MHC I and II, respectively,
induce diﬀerent types of T-cell responses [21, 22].
On the other hand, on the basis of the diﬀerent
phenotype and surface antigens, DCs could also be divided
into immature and mature DCs. The term “immature” refers
to DCs with the phenotypic features of low expression of
MHC II and molecules such as CD86. In contrast, mature
D C sa r ec h a r a c t e r i z e db yh i g he x p r e s s i o no fM H CI Ia n d
T-cell costimulatory molecules such as CD40, CD80, CD83,
and CD86 [23–25]. Under pathologic conditions, DCs are
stimulated by microbes, products of damaged tissues, cells
of the innate or adaptive immune system, and inﬂamma-
tory cytokines. These endogenous and exogenous antigens
are taken up by DCs through the specialized endocytic
system, which is mediated by a variety of receptors such
as Toll-like receptors (TLRs) [4, 26], nucleotide-binding,
and oligomerization domain proteins (NODs) [27, 28].
Then DCs undergo a complex process of activation making
immature antigen-capturing DCs change into APCs. The
process is characterized by extended dendrites of DC’s
external form. As a result, their cellular motility to migrate
to the draining lymph node is increased [29]. Meanwhile,
their surface costimulatory molecules such as CD40, CD80,
and CD86 are upregulated [30–32], and MHC molecules
are expressed on the surface of cells [33]. One of the
major functions of DCs in immune system is capturing
and presenting the antigen to T cells via MHC molecules.
When the antigen is presented by APCs through MHC I,
which interacts with CD8+ T cells, the activated T cells could
diﬀerentiateintocytotoxicTlymphocytes(CTLs).Activation
of CD4+ T cells occurs with the help of MHC II. After
activation, the CD4+ Tc e l l sd i ﬀerentiate into T-helper 1
(Th1) and T-helper 2 (Th2) cells, which are involved in
inducing macrophages and B-cells responses [34, 35]. CTLs
are the major killers of tumor cells; they accomplish the
killing with the help of CD4+ T cells, which can induce
potential long-term CD8+ T-cell responses by producing
various cytokines [36, 37].
Asitiswellknownthatintracellularendogenousantigens
and exogenous antigens are presented in MHC I and
M H CI Ib yD C s ,r e s p e c t i v e l y[ 38], the strategy for DC-
based vaccines in cancer immunotherapy is to make DCs
cross-presentation. This can present MHC I to CTLs using
internalized antigens generated from exogenous sources.
Through this process, TAAs can be presented by the DC to
both CD4+ and CD8+ T cells (in MHC I), and a broad and
strong immune response against tumor could be induced
[16, 39].
3.Methods UsedinGeneticallyEngineeredDCs
3.1. Modiﬁed/Pulsed Methods. It is generally believed that,
the direct presentation of TAAs to CD8+ CTLs (e.g., direct
administration of tumor peptides) is most tolerogenic [40,
41]. Several evidences showed that the diﬀerentiation and
maturation of DCs were suppressed by cytokines existing in
the tumor microenvironment. Since DCs play a crucial role
in inducing antigen-speciﬁc T-cell responses, it is important
to deliver tumor antigens with CD8+ and CD4+ T-cell
epitopes to DCs. There are several strategies to induce DCs
to present exogenous antigens on MHC I molecules [42].
According to the mechanism of MHC-mediated antigen
presentation, early researchers tried to pulse DCs directly
with tumor-speciﬁc peptides. Synthetic MHC I-binding
peptides have been used in DC-based vaccination. TheClinical and Developmental Immunology 3
TAAs, which were derived from MHC I-binding peptides,
including melanoma-related antigens [43, 44], carcinoem-
bryonic antigen (CEA) [45, 46], folate binding protein (FBP)
[47, 48], prostate-speciﬁc membrane antigen (PMSA) [49,
50], and Mucin 1 (MUC-1) [27, 51, 52], were ﬁrstly used
to modify DCs. This strategy was easy to perform and was
shown to be successful in some animal studies and clinical
trials. Further development in using Tat peptide, which is
from transduction domain of Human Immunodeﬁciency
Virus (HIV), makes this strategy more eﬀective [46, 53].
However, as this approach was mainly based on speciﬁc
MHC I-restricted peptides, the importance of MHC II-
restricted T-helper (Th) cells in mediating response (CD4+
T) and accelerating immune responses [54]w a sn o tf u l l y
considered.
Because of the limitations of using one single TAA
peptide to modify DCs, researchers began to design vac-
cination utilizing DCs pulsed with whole tumor lysates.
In this approach, as the tumor cell preparations contain
lots of relevant antigens, broad-spectrum TAAs including
unknown ones were presented to T cells and this induced
an immune response. The advantages of this method include
(1) presenting multiple peptides and epitopes to T cells to
induce CTL response; (2) generating both CD8+ response
and CD4+ helper T-cell response, which help to induce
macrophages and B-cell response as well as prolonging the
CTLsresponse;(3)reducingtheworkloadofdiscoveringand
preparing appropriate peptides and epitopes required to be
p r e s e n t e do nD C sa n dt h e nt ob ei d e n t i ﬁ e db yTc e l l s ;( 4 )
probably generating tumor lysate-speciﬁc memory T cells
[55]. The results in animal models and in clinic trials using
total tumor lysate approaches have been demonstrated to be
highly eﬀective and have low toxicity in a variety of cancers
[56, 57]. It was further observed that DCs pulsed with
apoptotictumorcellpreparationshowedamorepronounced
eﬀect in activating T cells [58]. The main limitation of this
method is the limited amount of patient tumor cells we
couldcollect,makingthepreparationworkdiﬃcult.Another
problem is that the presence of many irrelevant antigens in
tumor cell preparations could cause autoimmune responses.
Since the early reports on transfection with RNA showed
strong immune response against tumor [59, 60], mRNA-
pulsed DCs have become a research hotspot these days.
Because RNA-based vaccines have many advantages includ-
ing easily preparation, low price, speciﬁcity, control, and no
risk of incorporation into the host genome [61]. DCs were
transfected with tumor mRNA encoding TAA or epitopes by
using carriers [61, 62] or electroporation [63, 64]. This can
alsoinducetumor-speciﬁcimmunityinvitro.Bytransfection
with RNA, DCs can express speciﬁc or total antigen on
their surface and ﬁnally present them to T cells [65]. In
addition, using mRNA could be a promising therapy for
the patients who have only few available tumor cells for
mRNA preparation, because mRNA could be produced in
large amounts through noninvasive biopsy procedures [66].
Recent studies indicated that mRNA has been used not
only as a source of antigen, but also as a way to stimulate
DC to produce immunostimulatory molecules [67]. The
main limitations of using mRNA, however are diﬃculty in
manipulation, having lower transfer eﬃciency and shorter
lifespan (degradated by RNases rapidly) [68].
3.2. Modiﬁed/Pulsed Methods. To enhance DCs antitumor
eﬃciency, the delivery of DNA encoding TAAs, immunos-
timulatory molecules, cytokines, chemokines, and other
stimuli has been developed in the recent years. Compared
with tumor antigen loading strategies described previously,
genetical engineering of DCs has some special advantages,
which include: (1) bypassing the work of understanding
the complex intracellular process of MHC-mediated pre-
sentation; (2) achieving the purpose of cross presentation
to induce a robust immune response; (3) showing a long-
term antigen expression; (4) signiﬁcantly reducing the
autoimmune response; (5) easier preparation; (6) stability
in transduction process. However, there are also some
limitations in DNA-based DC vaccination. Immunother-
apy using DCs transferred by viral vectors may induce
an autoimmune response and mutation. Nonviral transfer
shows very low transfer eﬃciency. DNA strategy also has
its intrinsic problems such as persisting expression and
genome incorporation risk. These problems are needed to be
considered and solved before it becomes a better application.
To date, various vehicles and methods have been devel-
oped for gene transfer of DCs. Vehicles can be divided
into viral vectors and nonviral carriers. And there are also
some other transfection methods such as ultrasound and
electroporation. By using diﬀerent carries and transfection
methods, the transduction eﬃciency and the preclinic trial
results are diﬀerent [69, 70]. After long-term experiments
in vitro and in vivo, an increasing number of scholars
think that the transduction of DCs using vehicles shows
more advantages than using naked DNA alone. The major
advantage of using viral vectors is their high eﬃciency in
the transfection, which induced high protein expression
levels. The limitations of this method are immune and
mutation risk. For example, the host cells might express
the viral proteins, and thereby might induce immunologic
interference. In contrast, the nonviral strategy, which is
regarded as a safer alternative to virus-mediated transduc-
tion, is considered to be promising treatment in clinic.
Nonviral carriers could overcome the problems caused by
viral vectors. In addition, nonviral carriers were more stable
and controllable in preparation and application. The risk
of virus-associated recombination mutation in host genome
could be avoided. It makes DNA vaccines feasible in clinical
application. But the major limitations of nonviral carriers
are low eﬃciency in transfection and low levels of protein
expression. It needs to be optimized by the carriers modiﬁed
system. The mechanisms of transfection using viral vectors
and nonviral carriers are shown below (Figures 1 and 2).
3.2.1. DCs Transferred by Viral Vectors. In contrast with
direct viral vaccine, DCs transferred by viral vectors in vitro
would reduce the production of certain type of antibodies,
which may cause side eﬀects and would ﬁnally reduce the
eﬀectiveness of cancer therapy in clinic [71]. The viruses4 Clinical and Developmental Immunology
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Figure 1: The mechanism of transfection using nonviral carriers.
employed as gene vectors include adenoviruses (Ad), adeno-
associated viruses (AAV), retrovirus, lentivirus, and other
viruses. These viruses are all deleted critical genes needed
for their reproduction. And then, they are inserted with
purpose genes such as genes encoding TAAs. Recombinant
viral vectors might be the most attractive gene transduc-
tion vehicles because of their high transfection eﬃciency,
although they are more immunogenic than nonviral carriers
in clinical applications [72]. To minimize the risk of speciﬁc
immunity and to boost the clinical antitumor response,
severalimprovementsinviralstrategieshavebeendeveloped,
such as replacing the genes required for viral replication
with the helper plasmids and modifying the genome of
viral capsid [73]. However, to date, there is not a perfect
treatment for tumor by using viral vectors-transferred DCs,
astheapplicationofvirusesinvivocoulddestroytheantigen-
presenting function of DCs.
Adenovirus. Adenovirus (Ad), which is nonenveloped and
medium-sized (90–100nm) viruses, has a double-stranded
linear DNA genome. The adenoviral genome comprises four
early (E1, E2, E3, and E4), four intermediate, and one late
transcriptional units. To use Adas a gene-transferring vector,
the E1 gene, which contributes to reproduction, must be
deleted. Ad vectors (AdVs) are based on substitution of
the E1 region by the therapeutic gene. AdVs are widely
used for basic and clinical research because of their high
transduction eﬃciency [74–76]. The primary and secondary
binding receptors of AdVs, Coxsackie adenovirus receptor
(CAR), and V-integrin play important roles in mediating
the uptake of immature DCs. AdVs can consistently induce
potent presentation of both MHC class I and class II-
restricted epitopes. Several studies demonstrated that using
AdVs could be regarded as a valuable gene delivery system
even in clinical application, for example, serotype 5 (rAd5)
[77–80]. Interactions between AdVs and DCs were also
investigated recently. These include virus-mediated DC
maturation,antigenprocessingmachinery(APM)regulation
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Figure 2: The mechanism of transfection using viral vectors.
and T-cell activation. It was observed that the phenotype
and cytokine proﬁle of DC transduced with Ads changed
[81, 82], some selected modiﬁcation of DCs by Ads are
listed in Table 1. These results provide the evidence for the
designing human cancer vaccines.
Retrovirus and Lentivirus. Retrovirus is a single-stranded
(ss) RNA virus, which is replicated from RNA to DNA by
the revertase. Then the produced DNA is integrated into the
host’s genome by an integrase enzyme. With the replication
of host genome, the viruses reproduce as part of the host’s
DNA. Retroviruses also attract the DC researchers these
yearsfortheirtransductioncapacityofbonemarrow-derived
DCs (BMDCs) and cord blood-derived DCs to keep their
diﬀerentiation [93, 94]. The advantages of retroviral vectors
used as transduction vehicles include the stable expression
of full-length proteins and less immunologic responses
against viral antigens because their structural proteins are
not expressed [68]. However, most retroviruses are diﬃcult
to transfect nondividing cells such as mature DCs. This
disadvantage limits the application of retroviruses in clinic.
Lentiviruses derived from HIVs belong to retroviruses
family.Itiseasierforthelentivirustoinfectnondividing cells
compared to other retroviruses because of its unique route
of viral transfection by expressing both integrase [95]a n d
Vpx proteins which interact with components of the nuclear
pore complex [96, 97]. Another advantage of lentivirus is
the low prevalence of HIV infections, which lead relatively
rarepre-existingimmuneconditions[98].Thus,recombined
Lentivirusvectors(LVs)couldbedesignedaseﬃcientvectors
for transduction of both mature and immature DCs. Recent
studies have demonstrated that, in comparison with lipofec-
tion, electroporation and AAV, LV is the most eﬀective vector
for transduction of BMDCs [99]. Many studies reported that
the highly eﬃcient transduction of DCs in vivo [100–102]
and ex vivo [103] is possible by using LVs, this can be also
used for shRNA transduction [104, 105]. Moreover, LVs can
also be used to transfect monocytes before diﬀerentiatingClinical and Developmental Immunology 5
Table 1: Overview of recent studies using Ad vectors for gene transfer in DCs.
Cancer Transfer molecule In vitro In vivo in animal model Reference
Prostate tPSMA and 4-1BBL High IFN-production Strong antitumor immunity [83]
STEAP High IFN-production
Inhibition of tumor growth, vaccination
delaying the growth of pre-established
tumors
[84]
Hepatoma
mTERT High IFN-and IL-2
production Inhibition of the tumor growth [85]
hTERT Inducing strong CTL
response Inducing anti-tumour immunity [63]
HCC and CD40L Increasing DCs IL-12
Inducing complete regression of established
tumors and long-term immunity against
tumor recurrence
[86]
AFP and HBsAg Inducing CTLs killing
HepG2.2.15 cell lines
Inhibition of tumor growth in
immunodeﬁciency mice
[87]
Leukemia Survivin and GM-CSF
Much higher activity of
CTL than DCs with
either
No data available [88]
IL-12 with tumor cell lysate No data available Prolonged survival time [89]
Metastatic lung cancer IL-12- and 4-1BBL High IFN-production
and CTLs response
Greater antitumor and antimetastatic eﬀects
than either treatment alone higher
migratory abilities of DCs
[90]
Lung livin Inducing CTLs lysing
LLC
Inducing a potent protective and
therapeutic antitumor immunity
[91]
Urologic cancer cells Survivin
Inducing CTLs against
various bladder, kidney,
and prostate cancer cells
No data available [92]
into DCs, which could bypass the preactivation agents such
as granulocyte-macrophage colony-stimulating actor (GM-
CSF) and interleukin (IL)-4 [106]. Further modiﬁed work
has been performed these years and may be extended to
clinical trials. However, gene therapy using LVs has a possible
risk of insertional mutagenesis.
3.2.2. DCs Transferred by Nonviral Carriers. Although viral
vectors have been demonstrated to be more eﬃcient in gene
delivery, the clinical application is limited due to their risk
in safety and unexpected adverse eﬀects [107]. In contrast,
nonviral vectors, such as various liposomes and polyion
complexes, have been increasingly developed these years
because of their low immune response and ease of synthesis
under controllable conditions and ease to be modiﬁed. The
major limitations are their ineﬃcient transfer, low gene
expression and relatively high cytotoxicity by nature. Here is
the advanced development in several nonviral vectors.
Liposomes. Liposomes are artiﬁcial closed vesicles of lipid
bilayer membranes. Liposomes, modiﬁed with speciﬁc tar-
geting molecular structures on surface, can be used as
transfection vectors for DCs. After the APCs interact with
the targeting liposomes which contain antigen peptides
or DNA, the APC-mediated CTL responses are eﬀectively
enhanced [108]. Diﬀerent formulations of liposomes are
designed to improve the uptake by DCs through dif-
ferent receptor-mediated routes. These formulations of
liposomes include liposomes prepared with mannosylated
phosphatidylethanolamine(Man-PE),trimethylammonium
propane [2], and phosphatidylserine [109] corresponding to
mannose receptor (MR), negatively charged surface proteins
a n dP Sr e c e p t o ro fD C s ,r e s p e c t i v e l y[ 110].
Over the last decade, several studies have demonstrated
that MR-mediated gene transfer into macrophages and DCs
using mannosylated cationic liposomes can elicit eﬀective
immune responses [111–113]. MR is a typical receptor of C-
type lectins, which are structurally related to surface-bound
nonspeciﬁc pattern recognition receptors on the surface of
monocytes, macrophages, and DCs. Using the aﬃnity of
MR with mannose-containing ligands, researchers prepared
several mannosylated cationic liposomes to encapsulate
DNA or RNA for gene delivery purpose. It was also reported
that the transfection eﬃciency of macrophages and DCs was
enhanced by a combination method using mannosylated
lipoplexes and bubble liposomes (BLs) with ultrasound
exposure. In the liver and spleen, the transfection eﬃciency
by using this combination method was higher than that of
naked pDNA or combination of unmodiﬁed lipoplexes and
BLs [114]. Moreover, besides DNA delivery, siRNA silencing
of DCs with liposomes is also widely used [115, 116].
Fusogenic liposome (FL) encapsulating DNA is a novel
biological strategy to deliver antigen gene directly into
the cytoplasm of DCs via membrane fusion. It has been
demonstrated that FL-mediated OVA-gene delivery can
induce potent presentation of antigen via the MHC class
I-dependent pathway in vitro and then can induce a series6 Clinical and Developmental Immunology
of immune responses [117]. Complexes of lipoplexes with
pH-sensitive fusogenic liposomes can not only transfect
various malignant cells, but also can transfect a murine
DC line (DC2.4) [118]. These complexes exhibited higher
transfection eﬃciency to DC2.4 cells than some other
commercially available reagents. So these new complexes
may be valuable for the transfection of DCs.
Complex Particles. Recently, complex particles such as
cationic polymers have been used as promising vectors for
DNA delivery, because of their electrostatic interactions and
ease of modiﬁcation in targeting ligands. The advantages
of cationic polymers used as gene carriers include (1)
compression of the DNA into complex particles with small
size and high density, which makes gene easier to transfer
into cells; (2) electrostatic attraction with the cell membrane
to facilitate endocytosis; (3) stability under the electrostatic
repulsion. Nowadays, chitosan and biodegradable micropar-
ticles such as poly (ethylene-imine) (PEI), and so forth,
attracted considerable attention in this ﬁeld.
Chitosan has been used as gene delivery carrier because
of good biocompatibility and high positive charge density
in recent years [119]. The transfection eﬃciency of chitosan
depends on its molecular weight, DNA complexes charge
ratio, pH, and particle sizes as well as the type of cells
[120, 121]. To overcome the weakness of chitosan such as
poor solubility, low rate of DNA release and low eﬃciency of
transfection,hydrophilic,andhydrophobicstructuremodiﬁ-
cation have been carried out. Although unmodiﬁed chitosan
may not be a good gene delivery carrier for DCs because
of its low transfection eﬃciency, some modiﬁed chitosan
showed better behavior in delivering genes into DCs. For
example, to enhance the IL-12 gene delivery to DCs in
vivo, mannosylated chitosan (MC), which is used to induce
mannose receptor-mediated endocytosis, was prepared to
encapsulate IL-12 gene into DCs. MC not only has good
physicochemical properties and low cytotoxicity, but also
shows much more enhanced transfection eﬃciency to DCs
rather than unmodiﬁed chitosan in vitro.A n dt u m o rg r o w t h
in mouse model was suppressed by intratumoral injection of
MC/plasmid encoding murine IL-12 [122, 123]. Moreover,
Zhou et al. [124] developed MC microspheres containing
PEI/DNA complexes, and used this carrier to improve the
delivery of DNA into DCs. After in vivo immunization,
the microspheres induced signiﬁcantly enhanced serum
antibody and cytotoxic T-lymphocyte (CTL) responses.
Therefore, MC-mediated cytokine gene delivery system on
DCsmaybeapotentialapproachforcancerimmunotherapy.
Biodegradable microparticles which are easily cleared
by physiological clearance systems can avoid the possi-
ble cytotoxicity caused by accumulation in cells and tis-
sues. Microparticles prepared from poly (lactide) [125],
poly(lactide-coglycolide) (PLGA), poly (orthoesters) (POE),
and other polymers microparticles have been well studied
in recent years. Their biodegradability, biocompatibility,
and low toxicity properties make them suitable carriers for
DNA vaccines. The virus-associated risk of adverse eﬀects
can also be avoided because these microparticles do not
incorporate into the host cell’s nucleus. Several studies
have demonstrated that immune responses are induced
by particle-DNA vaccines. Recently, it was reported that
PLGA/PEI-DNA complex nanospheres have been developed
as an eﬃcient delivery system for the DCs. And the eﬃciency
can be signiﬁcantly promoted by modifying with nuclear
localization signal (NLS) [126]. Also, such material as POE
with lower cytoxicity was used to encapsulate plasmids and it
induced both cellular and humoral responses in vivo [127].
The internalization of the particles into DCs is through
phagocytosis, and the microparticles are easily phagocytosed
by DC in vitro or in vivo [128].
It is well known that PEI is the most eﬀective nonviral
carrier for gene delivery. It has relative high transfection
capacity due to its characteristics such as its ease in com-
bining with DNA, binding with the cell and escaping from
the endosome. Nowadays, the hotspots of research gradually
focused on reducing its toxicity by various modiﬁcations.
It is mainly because, cytotoxicity increases as the molecular
weight increases, while the eﬃciency of gene loading and
transfection increases correspondingly. Recently, Ali and
Mooney [129] demonstrated that it showed sustained and
long-term presentation when DCs were transfected with
the PEI condensed with gene encoding GM-CSF. And they
also use polymer PLG as scaﬀold fabrication continuously
stimulated DCs with both GM-CSF and PEI-DNA. This
process led to a 20-fold increase in gene expression than
no scaﬀold groups, and 10 days expression in vitro. These
results largely encouraged the development of biomaterials,
such as PEI, coordinated with other macroporous scaﬀolds
as a transfer system for DC-based vaccination. Besides, PEI-
based nanoparticles could also be used to encapsulate siRNA
to transfer DCs against tumor cells [130].
Transfection Systems for Nonviral Carriers Used in DCs
Transfer. Although nonviral gene delivery system has many
advantages as reported, it still cannot reach the high
transfection eﬃciency as viral vectors do, and the period
of transfection is also far from satisfactory. To improve
the eﬃciency, one of the methods is optimizing the whole
transfection system. For this purpose, the reverse and three-
dimensional (3D) transfection systems have been proposed.
Some earlier studies demonstrated that reverse transfec-
tion method was more eﬀective in enhancing the level and
duration of gene expression than that of the conventional
m e t h o do ns o m ec e l ll i n e s[ 133, 134]. This may be due
to the fact that DNA complexes can more easily transfect
cells if they are in the area nearer to cells. In addition, cells
tend to adhere to the surface and bottom of culture dish.
Thus, attaching theDNA-complexes to thebottom of culture
dishes before adding cells could enhance and prolong gene
expression.Moreover,continuousinteractionbetweenDNA-
complexes and cells would minimize the inﬂuence of serum
in the transfection activity of DNA-complexes.
Several physical, chemical, and biochemical factors, can
inﬂuence gene transfection eﬃciency. Increasing studies
have reported that, when cells are cultured in 3D sys-
tems, the results of transfection in various cells such asClinical and Developmental Immunology 7
Table 2: Genes used for modiﬁcation of DCs.
Groups Genes coding factors Eﬀects
TAAs Gp100, MART-1, PSA, CEA, MUC-1, p53, OVA,
LAMP
Lastingly expressing tumor antigens to induce the
adverse eﬀects of T-cells special response
Cytokines IL-2, IL-7, IL-12, IL-15, IL-18 [131, 132], IL-21,
IL-23, IFN, TNF-α
To enhance the activity of antigen-presenting function
of DCs,
Chemokines CCL21, CCL22, XCL1, CXCL9, CXCL19, CX3CL1 To guide lymphocytes to the lymph nodes
To have angiostatic activity
Costimulatory and
adhesion molecules
CD40L, CD70, 4-1BBL, OX40L RANKL, CD54,
CD58, CD80
To enhance APC’s ability to generate antitumor
immune responses
To improve adhesion interaction between DCs and T
cells
MSCs [135, 136] and HEK293T [137] showed higher
eﬃciency than results by using the conventional and reverse
methods. And in 3D systems, cells also exhibited better
morphology. The reasons may include (1) scaﬀolds provide
larger surface area and space for the interaction between
DNA-complexes and cells than that in two-dimensional
(2D) systems. (2) DNA complexes can be ﬁxed on the
scaﬀolds and prevented from aggregation in 3D systems. (3)
Signaling pathway can be inﬂuenced by 3D systems. Ali and
Mooney [129] reported that nonviral vector PEI/pDNA was
immobilized on a nonwoven fabric with reverse transfection
method. The scaﬀold was treated with negative charges
to facilitate the adsorption of cationic DNA/PEI complex.
DCs were eﬀectively transfected in this 3D system, and the
level of gene expression was signiﬁcantly higher than that
of conventional transfection. It should be noted that, to
date, the application of 3D or scaﬀold transfer system in
transfection of DCs is still a new area. So the methods of
cell seeding and the properties of the scaﬀold are still needed
further exploration.
4. Genes Employed in DCs Transfer
The DCs transferred with various genes can steadily and
eﬀectively express the proteins when DCs are refused ex
vivo. After being transferred with TAA genes, DCs could
express multiple antigens and epitopes. These antigens
can be cross presented to MHC. DCs transferred with
cytokines genes could produce large amounts of interleukin.
Diﬀerent genes encoding TAAs, cytokines, or chemokines
are utilized to engineer DCs to increase immunogenicity.
Subsequently,DCstransferredwiththegenesencodingTAAs
can present the encoded proteins to MHC molecules and
thentomediateT-cellresponses.WhenDCsweretransferred
with genes encoding cytokines such as IL-7 or IL-12, the
eﬃcacy of generating T cells and immune response can
be increased. When DCs were transferred with the genes
encoding chemokines, the chemotaxis of DCs to T cells can
be enhanced. Although this approach has not been used in
clinic, it would be a potential strategy for genetic engineering
technology on DCs. The genes used to transfer DCs are listed
in Table 2.
5. Effective Cancer Immunotherapy Induced by
Gene-TransferredDCs
In recent years, DC vaccines, especially DNA-based DC
vaccines, have been the focus of attention in cancer
immunotherapy. The main process is transferring DCs
in vitro, and then implanting them ex vivo. Finally, the
tumor-speciﬁc CTL response would be activated, and cancer
cells would be suppressed. These adoptive immunotherapy
approaches have been improved and have achieved partial
success in the treatment of malignant melanoma [34], renal
cell carcinoma [138], malignant lymphoma [139], and other
malignant diseases [109, 140]. Most of them were phase I/II
clinical trials.
Although various tumor types were studied, melanoma,
and prostate cancer are two predominant tumors treated
by gene-modiﬁed DC vaccine [141]. The clinical studies
for DC-based genetically modiﬁed vaccination include both
viral and nonviral approaches. In viral vaccinations, recom-
binant AdVs were mainly used, but their application in clinic
is limited by the biosafety concerns. In contrast, nonviral
carriers are widely used in clinical trials because of their low
toxicity. The major barrier of nonviral carriers is their low
transfer eﬃciency compared with viral vectors. In addition
to the gene delivery approach, the conformation of DCs
and the route of administration are also considered to be
the important issues. The formulation of DCs includes
not only monocytederived DCs and BMDCs, but also
immature and mature ones. The administration methods
mainly include intradermal, intravenous, intranodal, and
intratumoral delivery.
The above information suggests that DC-based vaccina-
tion against cancer is a promising approach with low adverse
eﬀects, but advanced eﬃcacy studies need to be carried out.
Despite this limitation, recombination DC vaccine would be
considered as an encouraging tool to treat cancer.
6. Conclusions andFuturePerspective
DC vaccines can kill the cancer cells with little damage
to normal cells by inducing and enhancing patient’s own
tumor-speciﬁcimmuneresponse.ThefunctionofDCscould
be to optimize genetic modiﬁcation by various TAAs or8 Clinical and Developmental Immunology
immune-modulatory molecules. Therefore, the application
of ex vivo DC-based vaccination for cancer immunother-
apy has many advantages because of its tumor-speciﬁc
stimulation. However, for clinical applications using DC
vaccines, lots of problems need to be solved, such as the low
aﬃnity between tumor epitopes and MHC, the frequency of
vaccine delivery and immune procedures, and the diﬃculty
to evaluate vaccines eﬀect. Until now, many researchers used
gene carriers and transfection systems in the recombination
of DCs for eﬀective cancer immunotherapy. With the
development of materials science, targeted cell biology and
molecularcytology,andsoforth,variousstrategieshavebeen
introduced to optimize both viral and nonviral vectors for
genedeliveryintoDCs.Inaddition,thereisarequirementfor
further investigation in the use of the reverse and 3D systems
to improve the nonviral transfection eﬃciency. These eﬀorts
are expected to facilitate future clinical applications of gene-
modiﬁed DCs for cancer therapy.
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